Rhythm Pharmaceuticals, Inc. (RYTM)

38,01 -0,95 (-2,44%) Börsenschluss: 04:00PM EDT

Rhythm Pharmaceuticals, Inc.

222 Berkeley Street
12th Floor
Boston, MA 02116
United States
857 264 4280
https://rhythmtx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 226

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. David P. Meeker M.D.	Chairman, President & CEO	1,35M	N/A	1954
Mr. Hunter C. Smith M.B.A.	CFO & Treasurer	757,32k	1,88M	1969
Mr. Joseph Shulman	Chief Technical Officer	677,27k	968,13k	1976
Mr. Yann Mazabraud	Executive VP & Head of International	936,91k	N/A	1973
Ms. Jennifer Lee	Executive VP & Head of North America	727,14k	779,08k	1976
Mr. Christopher German	Corporate Controller, Principal Accounting Officer & Executive Director	N/A	N/A	1971
Mr. David Connolly	Head of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Jim Flaherty	Senior VP & General Counsel	N/A	N/A	N/A
Ms. Sarah Ryan	Vice President of Sales & Marketing	N/A	N/A	N/A
Ms. Pamela J. Cramer	Chief Human Resources Officer	N/A	N/A	1975

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Corporate Governance

Rhythm Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 3, Vorstand: 8, Shareholderrechte: 8, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.